ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

CEPI

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa fever		University of Oxford	IAVI		
MERS	Uvax	IDT; Barinthus/ University of Oxford			
Nipah		PHV	University of Oxford		
Rift Valley fever	UC Davis; Afrigen	Wageningen U.	University of Oxford and KEMRI – Wellcome Trust		
Chikungunya					Valneva
COVID-19*					SK Bioscience; Biological E; Moderna; Clover; Novavax; AZ/Oxford; University of Hong Kong
Broadly protective Betacoronavirus	VIDO; Panacea/ THSTI; IVI consortium; Bharat/U Syd/ExcellGene; Intravacc		SK Bioscience		
Mpox			BioNTech		

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

CEPI

	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Disease X	Akagera POP BIO University of Queensland Gennova* University of Oxford Emervax Boost Biopharma HMRI ACM Bio Nagasaki University IVI consortium VitriVax Sinergium Abera Bioscience	Centivax Imperial	SK Bioscience	Moderna	
Filoviruses	Adaptvac Public Health Vaccines Stanford IAVI, with manufacturing by Hilleman** Oxford/ Leipzig/ Moderna Minapharm	University of Oxford/Serum Institute of India Moderna			

* Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.
** Hilleman will potentially support other CEPI funded rVSV vaccine candidates in the future.

All .

DISEASE	DEVELOPER	PHASE	TECHNOLOGY	CEPI FUNDING (IN USD)
 Lassa fever	University of Oxford	Phase I	Viral Vector	Up to $19 million‡
	IAVI	Phase II	Viral Vector	Up to $64.4 million
MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to $47 million‡
	IDT	Phase I	Viral vector	Up to $36 million
	Uvax bio	Preclinical	Protein based	Up to $2.6 million
 Nipah	University of Oxford	Phase II	Viral Vector	Up to $19 million‡
	Public Health Vaccines	Phase I	Viral vector	Up to $43.6 million
 Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to $40 million
	Wageningen University	Phase I	Live attenuated	Up to $38.4 million
	University of Oxford and KEMRI-Wellcome Trust	Phase II	Viral Vector	Up to $3.7 million
	Afrigen	Preclinical	mRNA	Up to $6.2 million
 Chikungunya	Valneva	Registration	Live attenuated	Up to $65.9 million
 COVID-19	SK Bioscience	Registration	Protein based	Up to $210 million
	Biological E	Registration	Protein based	Up to $14 million
	Moderna	Registration	Protein based	Up to $1 million
	Clover	Registration	Protein based	Up to $397.4 million
	University of Hong Kong	Registration	Live attenuated	Up to $5.4 million
	AZ/University of Oxford	Registration	Viral vector	Up to $384 million
	Novavax	Registration	Protein based	Up to $399 million
 Mpox	BioNTech	Phase II	mRNA	Up to $72 million**

(‡) Includes Lassa, MERS and Nipah funding

** Funding is part of a total investment of up to $90m.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

Broadly protective Betacoronavirus	IVI Consortium	Preclinical	mRNA	Up to $23.9 million
	VIDO	Preclinical	Protein based	Up to $22 million
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to $19.9 million
	SK Bioscience	Phase I/II	Protein based	Up to $50 million
	Panacea/THSTI	Preclinical	Protein based	Up to $12.5 million
	Intravacc	Preclinical	Protein based	Up to $4.8 million
Disease X	Abera Bioscience	Preclinical	Protein based	Up to $1.5 million
	Akagera	Preclinical	mRNA	Up to $1.5 million
	ACM Bio	Preclinical	mRNA	Up to $2.9 million
	Boost Biopharma	Preclinical	Protein based	Up to $5 million
	Centivax	Phase I	mRNA	Up to $5.0 million
	Gennova	Preclinical	mRNA	Up to $16.98 million‡‡
	HMRI	Preclinical	CircRNA	Up to $3.8 million
	Imperial College London	Phase I	SaRNA	Up to $15 million
	IVI, KDCA, ST Pharm, SNU	Preclinical	mRNA	Up to $16 million
	Moderna	Phase III	mRNA	Up to $54.3 million
	Nagasaki University	Preclinical	mRNA	Up to $5 million
	University of Oxford	Preclinical	Viral Vector	Up to $80 million
	POP BIO	Preclinical	Protein based	Up to $1.5 million
	University of Queensland	Preclinical	Protein based	Up to $10.6 million
	Sinergium	Preclinical	mRNA	Up to $1 million
	SK Bioscience	Phase I/II	mRNA	Up to $40 million
	VitriVax	Preclinical	Inactivated virus/Protein based	Up to $5 million

(‡‡) Includes $13.38 million for funding a Nipah candidate and $3.6 for funding for a Rabies candidate/platform optimisation.

Filoviruses	AdaptVac **(Broadly Protective)**	Preclinical	Virus-like particle	Up to $12.4 million
	Stanford School of Medicine **(Broadly Protective)**	Preclinical	Protein nanoparticle	Up to $18 million
	University of Oxford, Leipzig Institute for Drug Discovery, Moderna **(Broadly Protective)**	Preclinical	Viral vector and mRNA	Up to $26.7 million
	University of Oxford/ Serum Institute of India **(Bundibugyo)**	Phase I	Viral vector	Up to $13.9 million
	Moderna **(Bundibugyo)**	Phase I	mRNA	Up to $58.5 million
	IAVI **(Bundibugyo)** manufactured by Hilleman Laboratories	Preclinical	Viral vector	Up to $3.2 million for starter vaccine material + Up to $8.5 million to Hilleman Laboratories to advance development of rVSV vaccine and manufacture doses for clinical trials*
	Public Health Vaccines **(Bundibugyo)**	Preclinical	Viral vector	Up to $1.9 million
	Minapharm **(Bundibugyo)**	Preclinical	MVA platform	Up to $16.5 million

*Hilleman will potentially support other CEPI funded rVSV vaccine candidates in the future